MLYS
HealthcareMineralys Therapeutics, Inc.
$35.66
$-0.05 (-0.14%)
Jan 5, 2026
Price History (1Y)
Analysis
Mineralys Therapeutics, Inc. is a biotechnology company operating in the healthcare sector with a market capitalization of $2.82 billion and 51 employees. The company's industry classification falls under biotechnology. The financial health of Mineralys Therapeutics, Inc. is characterized by minimal profitability, with gross margin, operating margin, and profit margin all at 0.0%. Returns on equity and assets are also negative, standing at -42.1% and -26.5%, respectively. The company's balance sheet shows a significant amount of cash, totaling $593.63 million, while debt is not disclosed. The valuation context for Mineralys Therapeutics, Inc. includes a forward P/E ratio of -15.46 and an EV/EBITDA ratio of -12.13. These metrics provide a basis for evaluating the company's valuation in comparison to its peers within the biotechnology industry.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Visit website →Key Statistics
- Market Cap
- $2.82B
- P/E Ratio
- N/A
- 52-Week High
- $47.65
- 52-Week Low
- $8.24
- Avg Volume
- 1.49M
- Beta
- 0.49
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 51